Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2 -mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phas...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature communications Ročník 14; číslo 1; s. 630 - 12
Hlavní autori:	Harding, James J., Piha-Paul, Sarina A., Shah, Ronak H., Murphy, Jessica J., Cleary, James M., Shapiro, Geoffrey I., Quinn, David I., Braña, Irene, Moreno, Victor, Borad, Mitesh, Loi, Sherene, Spanggaard, Iben, Park, Haeseong, Ford, James M., Arnedos, Mónica, Stemmer, Salomon M., de la Fouchardiere, Christelle, Fountzilas, Christos, Zhang, Jie, DiPrimeo, Daniel, Savin, Casey, Duygu Selcuklu, S., Berger, Michael F., Eli, Lisa D., Meric-Bernstam, Funda, Jhaveri, Komal, Solit, David B., Abou-Alfa, Ghassan K.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 06.02.2023 Nature Publishing Group Nature Portfolio
Predmet:	45/23 692/4028/67/1059 692/4028/67/69 Anticancer properties Antineoplastic Combined Chemotherapy Protocols - adverse effects Biliary tract Biliary tract diseases Biliary Tract Neoplasms - chemically induced Biliary Tract Neoplasms - drug therapy Biliary Tract Neoplasms - genetics Breast Neoplasms - etiology c-Met protein Cancer Cholangiocarcinoma Diarrhea Diarrhea - chemically induced Enzyme inhibitors ErbB-2 protein Female Gallbladder Genomic analysis Humanities and Social Sciences Humans Kinases Medical prognosis multidisciplinary Mutants Mutation Patients Protein-tyrosine kinase Quinolines - pharmacology Quinolines - therapeutic use Receptor, ErbB-2 - genetics Safety Science Science (multidisciplinary) Solid tumors Survival Treatment Outcome Tumors Tyrosine
ISSN:	2041-1723, 2041-1723
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!